CRISPR Therapeutics has struck a deal with Anagenesis Biotechnologies, which has key technology for muscle stem cells. Together, they will tackle muscle disorders – including the rare disease Duchenne Muscular Dystrophy (DMD).
CRISPR Therapeutics (Basel, Switzerland) is the European champion of gene editing for health applications, a field that promises to revolutionize therapies – even if it’s in the middle of a patent war.
To bring this therapeutic revolution to reality, CRISPR Therapeutics’ strategy is far from going at it alone. The company has struck some massive deals in the last months. These include the €2.29Bn collaboration with Vertex Pharmaceuticals (US) and the €275M deal with Bayer (Germany).
Now, CRISPR Therapeutics is joining a new collaboration to its stack – with Anagenesis Biotechnologies, a Biotech specialized in muscle disorders.